Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Chatelle, Claire V ^a   Hövermann, Désirée ^a   Müller, Anne ^a   Wagner, Hanna J ^a   Weber, Wilfried ^a   Radziwill, Gerald ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; DABRAFENIB; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; OXIME; PROTEIN KINASE INHIBITOR; RAF PROTEIN; SULFONAMIDE; VEMURAFENIB;

ANTAGONISTS AND INHIBITORS; DRUG SCREENING; ENZYME INDUCTION; GENETICS; HEK293 CELL LINE; HELA CELL LINE; HUMAN; METABOLISM; OPTOGENETICS; PHOSPHORYLATION; PROTEIN PROCESSING; RADIATION RESPONSE; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INDUCTION; HEK293 CELLS; HELA CELLS; HUMANS; IMIDAZOLES; INDOLES; OPTOGENETICS; OXIMES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 84962449962     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep23713     Document Type: Article

References (28)

1. Lavoie, H. & Therrien, M. Regulation of RAF protein kinases in ERK signalling. Nat Rev Mol Cell Biol. 16, 281-298, doi: 10.1038/ nrm3979 (2015).
2. Tian, T. et al. Plasma membrane nanoswitches generate high-fidelity Ras signal transduction. Nat Cell Biol. 9, 905-914, doi: 10.1038/ ncb1615 (2007).
3. Baljuls, A., Kholodenko, B. N. & Kolch, W. It takes two to tango-signalling by dimeric Raf kinases. Mol Biosyst. 9, 551-558, doi: 10.1039/c2mb25393c (2013).
4. Wellbrock, C., Karasarides, M. & Marais, R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol. 5, 875-885, doi: 10.1038/ nrm1498 (2004).
5. Hu, J. et al. Allosteric activation of functionally asymmetric RAF kinase dimers. Cell 154, 1036-1046, doi: 10.1016/j.cell.2013.07.046 (2013).
6. Brose, M. S. et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62, 6997-7000 (2002).
7. Wan, P. T. et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867 (2004).
8. Heidorn, S. J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221, doi: 10.1016/j.cell.2009.12.040 (2010).
9. Hertzman Johansson, C. & Egyhazi Brage, S. BRAF inhibitors in cancer therapy. Pharmacol Ther. 142, 176-182, doi: 10.1016/j. pharmthera.2013.11.011 (2014).
10. Rahman, M. A., Salajegheh, A., Smith, R. A. & Lam, A. K. BRAF inhibitors: From the laboratory to clinical trials. Crit Rev Oncol Hematol. 90, 220-232, doi: 10.1016/j.critrevonc.2013.12.008 (2014).
11. Carnahan, J. et al. Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth. Mol Cancer Ther. 9, 2399-2410, doi: 10.1158/1535-7163.MCT-10-0181 (2010).
12. Hatzivassiliou, G. et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431-435, doi: 10.1038/nature08833 (2010).
13. Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. & Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430, doi: 10.1038/nature08902 (2010).
14. Holderfield, M., Deuker, M. M., McCormick, F. & McMahon, M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer 14, 455-467, doi: 10.1038/nrc3760 (2014).
15. Tischer, D. & Weiner, O. D. Illuminating cell signalling with optogenetic tools. Nat Rev Mol Cell Biol. 15, 551-558, doi: 10.1038/ nrm3837 (2014).
16. Beyer, H. M., Naumann, S., Weber, W. & Radziwill, G. Optogenetic control of signaling in mammalian cells. Biotechnol J 10, 273-283, doi: 10.1002/biot.201400077 (2015).
17. Zhang, K. et al. Light-Mediated Kinetic Control Reveals the Temporal Effect of the Raf/MEK/ERK Pathway in PC12 Cell Neurite Outgrowth. Plos ONE 9, doi: 10.1371/journal.pone.0092917 (2014).
18. Wend, S. et al. Optogenetic control of protein kinase activity in mammalian cells. ACS Synth Biol. 3, 280-285, doi: 10.1021/ sb400090s (2014).
19. Kennedy, M. J. et al. Rapid blue-light-mediated induction of protein interactions in living cells. Nat Methods 7, 973-975, doi: 10.1038/nmeth.1524 (2010).
20. Bugaj, L. J., Choksi, A. T., Mesuda, C. K., Kane, R. S. & Schaffer, D. V. Optogenetic protein clustering and signaling activation in mammalian cells. Nat Methods 10, 249-252, doi: 10.1038/nmeth.2360 (2013).
21. Rushworth, L. K., Hindley, A. D., O'Neill, E. & Kolch, W. Regulation and Role of Raf-1/B-Raf Heterodimerization. Mol Cell Biol. 26, 2262-2272, doi: 10.1128/MCB.26.6.2262-2272.2006 (2006).
22. Chin, P. C. et al. The c-Raf inhibitor GW5074 provides neuroprotection in vitro and in an animal model of neurodegeneration through a MEK-ERK and Akt-independent mechanism. J Neurochem. 90, 595-608, doi: 10.1111/j.1471-4159.2004.02530.x (2004).
23. King, A. J. et al. Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions. Plos One 8, e67583, doi: 10.1371/journal.pone.0067583 (2013).
24. Holderfield, M. et al. RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation. Cancer Cell 23, 594-602, doi: 10.1016/j.ccr.2013.03.033 (2013).
25. Lavoie, H. et al. Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization. Nat Chem Biol. 9, 428-436, doi: 10.1038/nchembio.1257 (2013).
26. Arora, R. et al. Structural investigation of B-Raf paradox breaker and inducer inhibitors. J Med Chem. 58, 1818-1831, doi: 10.1021/ jm501667n (2015).
27. Hirata, E. et al. Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin beta1/FAK signaling. Cancer Cell 27, 574-588, doi: 10.1016/j.ccell.2015.03.008 (2015).
28. Ziogas, A., Moelling, K. & Radziwill, G. CNK1 is a scaffold protein that regulates Src-mediated Raf-1 activation. J Biol Chem. 280, 24205-24211, doi: 10.1074/jbc.M413327200 (2005).